BioSpace News Archive

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is taking place on April 25 – 26, 2023.

Schrödinger, Inc. today reported that on April 14, 2023, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSU) with respect to 1,800 shares of the company’s common stock to one newly hired employee.

Vistagen today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C.

PHM Brands™, a vertically integrated agricultural and biotechnology company and owner of multiple subsidiaries, including growing flour miller Panhandle Milling™, announced that Gina Steffens, PHM Brands former Chief Legal Officer, would be succeeding John Mason and Bryan Ledgerwood as PHM Brands’ Chief Executive Officer.

When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit.

Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, held from April 14 to 19, 2023.

OncoResponse today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.

Cognition Therapeutics , Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD).

Surmodics, Inc. today announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is proud to announce its participation at the upcoming Sequire Investor Summit.